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ABSTRACT Dengueviruses(DENV)causeaspectrumofdiseaseinhumans,rangingfromdenguefever(DF)toasevere,life-
threateningsyndromecalleddenguehemorrhagicfever/dengueshocksyndrome(DHF/DSS).Despitetheglobalmorbidityand
mortalityassociatedwithDENVinfection,mechanismsofimmunecontrolandviralpathogenesisarepoorlyunderstood.Ina
recentarticle,Avirutnanetal.[mBio2(6):e00276-11,2011]demonstratedthatDENVcanbedirectlyneutralizedviathemannose
bindinglectin(MBL)pathwayofthecomplementsystemandthatdeﬁciencyinMBLleveloractivityduetohostpolymorphisms
intheMBL2genecorrelateswithreducedlevelsofDENVneutralization.TheseﬁndingsimplicatearolefortheMBLpathwayin
controllingDENVinfectionsandmodulatingDHF/DSSmanifestations.
T
he four serotypes of dengue viruses (DENV) cause 100 to 500
millioninfectionseachyearinover100countries,resultingin
40 million clinically apparent cases and 20,000 deaths (1). The
clinically apparent cases represent a spectrum of illnesses ranging
fromanacutefebrilediseasecalleddenguefever(DF)tothesevere
andlife-threateningdenguehemorrhagicfever/dengueshocksyn-
drome(DHF/DSS).Severediseaseispreferentiallyassociatedwith
secondary infection with a different serotype and with primary
infection of infants born to DENV-immune mothers. To explain
these epidemiological observations, a process called antibody-
dependentenhancementofinfection(ADE)hasbeenproposedto
explainDENVpathogenesis(2).Twootherdominanthypotheses
intheﬁeldinvolveserotype-cross-reactivememoryTcells(3)and
viralvirulence(4).Thesethree,non-mutually-exclusiveprocesses
are postulated to increase viral load and trigger “cytokine storm”
and activation of the complement system, resulting in DHF/DSS.
The precise mechanism of DHF/DSS pathogenesis and the rela-
tionships between viral load, cytokine storm, and complement
activation are uncertain. Moreover, host genetic factors may in-
ﬂuencediseasepathogenesis,aspolymorphismspresentinseveral
host immune response genes, including those encoding tumor
necrosisfactor(TNF),DC-SIGN,andFcRIIa(5),havebeencor-
related with altered susceptibility to DHF/DSS. However, the
virus-host interactions that lead to protective immunity as op-
posed to disease pathogenesis have yet to be elucidated. In fact,
littleisknownaboutthemechanismsofanti-DENVimmunity,as
most studies to date have focused on examining the role of the
immunesysteminthecontextofpathogenesis.Understandingthe
mechanismsthatregulatethebalancebetweenimmune-mediated
pathology and protection is critical for developing safe and effec-
tive treatments and vaccines against DENV.
TherecentstudybyAvirutnanetal.(6)beginstoshedlighton
the dual role of the complement system in protection against and
pathogenesis of DENV infection. The complement system, com-
posed of over 30 different soluble and cell surface proteins, is an
important component of innate immune responses against vari-
ous pathogens. It is activated via the classical, lectin, and alterna-
tive pathways, and it controls viral infections through multiple
mechanisms, including lysis of virions or infected cells, produc-
tionofanaphylatoxins,andprimingofTandBcellresponses.The
classical pathway is activated by C1q binding to antigen-antibody
complexes; the lectin pathway involves recognition of carbohy-
drate structures on pathogens by mannose binding lectin (MBL);
and the alternative pathway is constitutively active at low levels
throughspontaneoushydrolysisofC3(reviewedinreference7).A
majority of studies examining complement-DENV interactions
have focused on the role of complement in the context of DHF/
DSS pathogenesis. In particular, a retrospective clinical study has
shown that excessive consumption of complement proteins cor-
relatedwithDHF/DSS(8),andaninvitrostudyhasdemonstrated
that complement could enhance DENV infection of myeloid cells
by promoting viral entry through CR3 (9). Based on these earlier
studiessuggestingthatcomplementactivationispathogenic,later
studies have examined potential mechanisms of complement ac-
tivation in DHF/DSS cases. In an in vitro study, anti-DENV anti-
bodies could activate complement on the surface of infected en-
dothelial cells (10). In a prospective study, the DENV
nonstructural protein 1 (NS1) could activate complement, and
levels of NS1 and several complement proteins correlated with
disease severity (11). In another prospective study, the levels of
complement factors D and H (i.e., regulatory proteins of the al-
ternative pathway) and the MBL protein were found to be higher
in DHF patients than in DF individuals (12). These later studies
thus supported the earlier studies by postulating a relationship
between NS1 activity and complement activation (11) or an al-
tered regulation of complement activation (12) in dengue patho-
genesis. However, recent ﬁndings have begun to suggest a role for
the complement system in the context of protective immunity. In
particular, in vitro ADE studies have demonstrated that comple-
ment proteins reduce DENV infection (13, 14), suggesting that
complement may play a role in limiting ADE-mediated disease.
More recently, in vitro studies with DENV NS1 have shown that
this viral protein binds C4 and C1s (15) or C4BP (16) to antago-
nize complement activation, implicating NS1 as an immune eva-
sion molecule in vivo. These most recent studies showing how
DENVmayemploymultiplemechanismstosubvertcomplement
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player in the host defense against DENV. Avirutnan et al. (6) ex-
amined the role of the complement system in protection against
DENVinfection,andtheresultsprovidesupportforanimportant
roleofthecomplementsystemincontrollingDENVinfectionand
potentially inﬂuencing the severity of dengue disease in humans.
Speciﬁcally,Avirutnanetal.performedinitialexperimentsus-
ing naive mouse sera to determine which complement pathways
contribute to neutralization of DENV in vitro (6). Experiments
withloss-of-functionmodelsforvariousmousecomplementpro-
teinsdemonstratedthattheMBLpathwaywascriticalforneutral-
ization of both insect and mammalian cell-derived DENV sero-
type 2 (DENV2), although insect cell-derived DENV2 was
neutralized more efﬁciently than mammalian cell-derived virus.
Based on these results, the authors performed additional experi-
ments using puriﬁed human MBL and showed that MBL could
directlyneutralizeinsectbutnotmammaliancell-derivedDENV2
in the absence of other complement proteins and that this direct
MBL-mediated neutralization was more efﬁcient at higher tem-
peratures (37°C and 40°C) than at room temperature. Further
experiments using puriﬁed human MBL and serum from MBL-
deﬁcient mice showed that MBL-mediated neutralization of in-
sectcell-derivedDENV2wasenhancedbyothercomplementpro-
teins. Similar to results obtained with mouse sera, human sera
from some individuals could neutralize both insect and mamma-
lian cell-derived DENV2 in an MBL-dependent manner. In this
case, neutralization of insect cell-derived DENV2 was more efﬁ-
cient than that of mammalian cell-derived virus. Sera from other
individuals neutralized only insect cell-derived DENV2, not
mammalian cell-derived DENV2. A positive correlation was ob-
served between the MBL concentration in human serum and the
levelofDENV2neutralizingactivity.Moreover,experimentswith
sera obtained from individuals with different levels of MBL2 due
to known polymorphisms in the MBL2 gene corroborated the
positive correlation between human MBL2 levels and neutraliza-
tionofinsectcell-derivedDENV2.Finally,experimentswereper-
formed with both mouse and human serum samples to show that
the MBL pathway could neutralize the remaining three serotypes
other than DENV2. Collectively, these results tie together initial
observations made using mouse models and human donors to
subsequent ﬁndings related to humans with particular polymor-
phisms in the MBL2 gene and suggest that the MBL pathway con-
tributes to protection against DENV infection in humans.
Based on the ﬁndings of this study, a depressed level of MBL
protein or activity may be an independent risk factor for morbid-
ity and mortality associated with DENV infection. Deﬁciencies in
MBL are relatively common in humans. MBL deﬁciency has been
associated with increased susceptibility to many infectious dis-
eases, including viral infections (17), and MBL2 polymorphisms
havebeenassociatedwithdiseasepathogenesis(18).Examination
of a limited number of Vietnamese individuals with low serum
MBL concentrations due to a variant MBL allele suggested that
MBL deﬁciency does not impact the risk of DHF/DSS (5). How-
ever,studieswithDENV-infectedpatientsinBrazilsuggestedthat
low levels of MBL may be associated with protection against
thrombocytopenia (19), whereas high MBL levels appear to be
correlated with severe disease (12). Accumulating evidence indi-
cates that DF and DHF/DSS are complex diseases that are likely
affected by multiple viral and host immune and genetic factors.
Futurestudieswithstatisticallysigniﬁcantnumbersofindividuals
with the same MBL genotypes analyzed in the published studies
and with individuals with other known MBL2 gene polymor-
phismsthatareassociatedwithdecreasedMBLlevelsshouldclar-
ify the precise role of the MBL pathway in determining the out-
come of DENV infection.
Thepresentstudyhasthusprovidedanimpetusforinvestigat-
ing the role of the MBL pathway and other elements of the com-
plement system in anti-DENV protection versus disease patho-
genesis using animal models and patient samples. This line of
researchmayhelpanswertwocentralquestionsintheDENVﬁeld:
why are the vast majority of individuals with either primary or
secondaryDENVinfectionsasymptomatic,andwhydosecondary
infections with DENV result in more severe illness than primary
infections?
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